Are the prescriptions of anticholinesterasic drugs adapted to the associated diseases and/or drugs in the Alzheimer's dementia?;Les prescriptions de médicaments anticholinestérasiques sont-elles adaptées au contexte médical au cours de la démence de type Alzheimer?

Therapie

Volumn 61, Issue 1, 2006, Pages 23-27

  Doucet, Jean ^a   Kalimoutou, Sendil ^a   Chédru, Christine ^a   Remy, Elise ^a   Cabrejo, Lucie ^a   Méliot, Cécile ^a   Chassagne, Philippe ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Anticholinergic drugs; Anticholinesterase drugs; Drug drug interactions; Inappropriated prescriptions

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NEUROLEPTIC AGENT; RIVASTIGMINE; HYPOCHOLESTEROLEMIC AGENT;

AGED; ALZHEIMER DISEASE; ANAMNESIS; ATRIOVENTRICULAR BLOCK; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE DISEASE; URINE RETENTION; ARTICLE; DRUG INTERACTION; FEMALE; MALE; PATIENT SELECTION; STATISTICS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; PATIENT SELECTION; PRESCRIPTIONS, DRUG;

EID: 33747065599     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006016     Document Type: Conference Paper

References (25)

1. Dictionnaire Vidal 2005, Ed Vidal. Available on http://www.vidal.fr
2. Ankri J. Les traitements de la maladie d'Alzheimer. Rev Neurol 2003; 159: 819-824
3. Ramaroson H, Helmer C, Barberger-Gateau P, et al. Prévalence de la démence et de la maladie d'Alzheimer chez les personnes de 75 ans et plus: données réactualisées de la cohorte PAQUID. Rev Neurol 2003; 159: 405-411
4. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Cur Med Res Opin 2002; 18: 129-138
5. Cummings JL. Alzheimer's disease. N Eng J Med 2004; 351: 56-67
6. Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 58-67
7. Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-789
8. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-446
9. Bryson HM, Benfield P. Donezepil. Drugs Aging 1997; 10: 234-239
10. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998; 13: 391-411
11. Schuck S, Bentue-Ferrer D, Beaufils C, et al. Effets indésirables et médicaments de la maladie d'Alzheimer. Therapie 1999; 54: 237-242
12. Hager K, Calabrese P, Frölich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15: 189-198
13. Scott LJ, Goa KL. Galantamine. A review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-1122
14. Sthal SM, Markowitz JS, Gutterman EM, et al. Co-Use of donepezil and hypnotics among Alzheimer's disease patients living in the community. J Clin Psychiatry 2003; 64: 466-472
15. Dartigues JF, Goulley F, Bourdeix I, et al. Utilisation de la rivastigmine en pratique médicale courante chez des patients ambulatoires présentant une maladie d'Alzheimer. Rev Neurol 2002; 158: 807-812
16. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031
17. Winblad B, Engedal K, Soininien H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer's dementia. Neurology 2001; 57: 489-495
18. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, Gilman AG. editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 10th ed. New York: Mac Graw Hill, 2001: 175-191
19. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. JAGS 2002; 50: 836-842
20. Huang F, Lasseter KC, Janssens L. et al. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol 2002; 42: 1341-1351
21. Zhao Q, Xie C, Pesco-Koplowitz L, et al. Pharmacokinetic and safety assessments of concurrent administration of risperidone and donepezil. J Clin Pharmacol 2003; 43: 180-186
22. Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderate severe Alzheimer's disease. Int J Ger Psychopharmacol 1998; 1: 55-65
23. Mohs RC, Doody RS, Morris JC, et al. A one-year, placebo-controlled preservation of function survival study of donepezil in Alzheimer's disease patients. Neurology 2001; 57: 481-488
24. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115
25. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 1999; 318: 633-640